By staff writers

October 1, 2013 -- The Medical Imaging and Technology Alliance (MITA) cited progress in the U.S. Centers for Medicare and Medicaid Services' (CMS) final decision on beta-amyloid PET coverage; however, the organization said it was disappointed by the scope.

On September 27, CMS issued a final decision approving beta-amyloid PET under the agency's coverage with evidence development (CED) protocol for patients enrolled in an approved clinical study.

Although MITA appreciates that CMS is offering beta-amyloid PET to some Medicare beneficiaries, the group is disappointed there will not be coverage for beta-amyloid PET without CED for patients with suspected dementia or Alzheimer's disease who meet specific appropriate-use criteria.

The organization will continue to work with CMS toward a substantive, feasible CED program that will support broader access for Medicare patients, according to Gail Rodriguez, executive director of MITA.

Copyright © 2013

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking